Many symptoms of Parkinson's are also common side effects of normal aging making an accurate diagnosis of Parkinson’s a challenging task. ClearSky Medical Diagnostics specialises in developing technologies for the diagnosis and monitoring of #Parkinsons . clearskymd.com/products/

"It is an excellent match that Accurature and ClearSky will work together to introduce an AI-based diagnostic device for #Parkinsons in China." 𝐽𝑎𝑐𝑘𝑖𝑒 𝐻𝑜, 𝐶𝐸𝑂 𝑜𝑓 𝑆ℎ𝑎𝑛𝑔ℎ𝑎𝑖 𝐴𝑐𝑐𝑢𝑟𝑎𝑡𝑢𝑟𝑒 𝐷𝑖𝑎𝑔𝑛𝑜𝑠𝑡𝑖𝑐𝑠 clearskymd.com/clearsky-secur…

ClearSky MD has been named 'One to Watch' in the inaugural Tech Climbers Leeds City Region initiative. The Tech Climbers mission is to showcase and celebrate scaling tech businesses in growth regions across the UK.

Prof. Stephen Smith is presenting a session on #machinelearning for measuring improvements in rehabilitation programmes for #Parkinsons at the PD Warrior 2022 Insight conference on 13 April during #ParkinsonsAwarenessMonth. 👇 pdwarrior.com/insight/

We're exhibiting at the Global Conference of Alzheimer's Disease International @alzdisint, the global voice on #dementia, in June & would love to meet you! Get in touch to discuss our MCI-Monitor for objectively detecting mild cognitive impairment. clearskymd.com/meet-clearsky-…

ClearSky Medical Diagnostics is supporting an initiative to better understand the development of children’s brains during their early stages of life. clearskymd.com/clearskys-ai-t…

ClearSky's Prof Smith discusses disruptive healthcare technologies in #neurodegenerative diseases in the latest SCOR Innovation Podcast. Stephen highlights the challenges of diagnosing #Parkinsons & our work in #machinelearning. podcasts.apple.com/us/podcast/dis…

We will be attending the International Parkinson & Movement Disorder Society Congress in Spain this month with MDS. Pop by Booth 104 to meet up with Professor Stephen Smith, our co-founder & MD. #MDSCongress clearskymd.com/clearsky-heads…

ClearSky’s co-founder Professor Stephen Smith discusses disruptive healthcare technologies in neurodegenerative diseases in the recent SCOR Innovation Podcast. Listen here 🎧 clearskymd.com/scor-innovatio…

The ClearSky MD team is at the MDS MDS Congress in Madrid this week. Pop by to say hello at Booth 104. #MDSCongress #mds2022

ClearSky is at MEDICA, the world’s largest event for the medical sector. Meet Cameron Harwood, our head of product development, in Hall 16, stand number J48. We're proud to be part of UK Healthcare Pavilion supported by @tradegovuk. #medtech #medica2022 #medica

This week, we're in Düsseldorf for #medica2022. On Tuesday, our head of product development delivered a presentation on The Objective Assessment of #Parkinsons in the UK Healthcare Pavilion Presentation Theatre. Pop by Hall 16, stand number J48 to learn more about our technology.

Great to hear from ClearSky MD this week at MEDICA. Another one of the excellent @tradegovuk innovator showcase companies. They are doing some brilliant work developing technologies for the diagnosis and monitoring of Parkinson's!

After two days in Dubai at #ArabHealth2023, I was bowled over by some of the UK-based innovations on display 🇬🇧🇦🇪 🇬🇧The UK was the 2nd largest country on display! ⚕️Some of these innovations will help solve some of the healthcare issues being faced by people across the world

We've been selected as a UK #LifeSciences Innovator 2023 by @tradegovuk. After a rigorous selection process, we are one of 57 companies chosen to showcase the best of #UKinnovation at global life sciences events across 2023.#LSI2023 clearskymd.com/clearsky-md-is…

Fantastic to chat about our technology for diagnosing and monitoring neurodegenerative conditions, including #parkinsons and #alzheimers at the 2023 MDS Congress (#MDSCongress) in Copenhagen this week.

Check out my blog post wix.to/d1i8x2S #newblogpost

Check out my blog post wix.to/9xcrPDf #newblogpost

Check out my blog post wix.to/xZidxq2 #newblogpost

🚀 New from ClearSky MD: TAP-HD study shows digital motor & eye-tracking can capture subtle Huntington’s disease changes—even outside clinics. 205 participants, AI-powered platform, big potential for trials & care. 👉 Link